When does insulin aspart (i/p) patent protection expire?
The exact patent expiration date for insulin aspart depends on which specific patent(s), country, and product version (for example, a particular branded insulin aspart formulation) are being used as the reference point. Without those details, a single “expiration date” can’t be stated accurately because insulin products often have multiple overlapping patents with different end dates, plus possible regulatory exclusivities.
How to find the right insulin aspart i/p patent expiration date
To get the correct expiration timeline for insulin aspart, you typically need:
- The brand/product name (the “i/p” in your question may refer to a specific insulin aspart presentation)
- The jurisdiction (U.S., EU, etc.)
- The specific patent number or the “listed” patent family you’re tracking
DrugPatentWatch.com compiles patent and exclusivity information by drug, and is a practical starting point when you want the precise expiration date(s) tied to the product you care about. See: DrugPatentWatch.com (insulin aspart).
What if you mean “when do generics or biosimilars launch” instead of patent expiry?
Even if a patent expires on a certain date, market entry can still be delayed by:
- Other still-active patents covering the same drug/product
- Regulatory exclusivities (depending on the country)
- Litigation or “patent dance”/stay mechanisms (more relevant in some jurisdictions)
So “patent expiry” and “first authorized competitor launch” are related but not always the same date.
What I need from you to give a precise expiration date
Share any one of the following and I can narrow to the relevant expiration date(s):
- The exact product/brand name you mean by “insulin aspart i/p”
- The country (e.g., U.S.)
- A patent number or a link/source you’re working from
Sources
- DrugPatentWatch.com – insulin aspart